Hampel, H. et al. Perspective on future role of biological markers in clinical therapy trials of Alzheimer’s disease: A long-range point of view beyond 2020. Biochem. Pharmacol. 88, 426–449. https://doi.org/10.1016/j.bcp.2013.11.009 (2014).
Blennow, K., Hampel, H. & Zetterberg, H. Biomarkers in Amyloid-(upbeta ) immunotherapy trials in Alzheimer’s disease. Neuropsychopharmacology 39, 189–201. https://doi.org/10.1038/npp.2013.154 (2014).
Lista, S. et al. CSF A(upbeta ) 1–42 combined with neuroimaging biomarkers in the early detection, diagnosis and prediction of Alzheimer’s disease. Alzheimer’s Dementia 10, 381–392. https://doi.org/10.1016/j.jalz.2013.04.506 (2014).
